Study Claim: Inflammation-mediated cancer-cell progression can be prevented by GliSODin brand superoxide dismutase.
Published: Okada F, et al. Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase. British Journal of Cancer 2006;94:854-62.
Abstract: GliSODin is a cantaloupe melon extract rich in vegetal superoxide dismutase covered by polymeric films of wheat matrix gliadin. This is the only proven orally effective delivery of superoxide dismutase. Weakly tumourigenic and nonmetastatic QR-32 cells derived from a fibrosarcoma in C57BL6 mouse are converted to malignant cells once they have grown after being co-implanted with a gelatin sponge, which induces inflammation. We administered a newly developed peroral superoxide dismutase (SOD), oxykine, and as control vehicle, gliadin and saline, starting two days before the co-implantation and continued daily throughout the experiment. In the oxykine group, tumour incidence was 41 per cent lower than in the gliadin or saline group (83 and 79 per cent, respectively).
The inhibitory effect of oxykine was lost when an individual component of oxykine was administered, that is, SOD alone and gliadin alone. The effect was also abolished when administered by intraperitoneal route. When perfused in situ with nitroblue tetrazolium, an indicator of superoxide formation, the tumour masses from the gliadin and saline groups displayed intense formazan deposition, whereas those from the oxykine group had less deposition. Enzymatic activity of SOD was also increased in the oxykine group. Arising tumour cells in the gliadin and saline groups acquired metastatic phenotype, but those in the oxykine group showed reduced metastatic ability.
These results suggested that the orally active SOD derivative prevented tumour progression promoted by inflammation, which is thought to be through scavenging inflammatory cell-derived superoxide anion.
Potential applications: GliSODin, available as an oral supplement, demonstrates anti-inflammatory properties. Previous research also shows this natural antioxidant enzyme to be an immunomodulatory agent.
+1 973 984 0900, x215
Study claim: Lycopene is an effective chemopreventive agent in the treatment of prostate cancer, with no toxicity and good patient tolerance.
Published: Mohanty NK, et al. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urologic Oncology 2005 Nov-Dec;23(6):383-5.
Abstract: Prostate cancer is one of the biggest cancer killers in industrial countries and affects more than half a million men worldwide every year. Because of its long latency, slow-growing nature and high prevalence, prostate cancer is the best model for chemoprevention studies. High-grade prostate intraepithelial neoplasia (HGPIN) is a precursor of prostate cancer. Chemoprevention with lycopene has shown definite results in prostate cancer. We undertook a study to use lycopene as a chemopreventive agent in the treatment of HGPIN for preventing prostate cancer from developing in this vulnerable group of patients.
A total of 40 patients with HGPIN were randomised into two groups: one received 4mg lycopene twice a day for one year, and the other was periodically followed up. Total follow-up was one year. Results showed that lycopene can delay or prevent HGPIN from developing into occult prostate cancer, and there exists an inverse relationship between lycopene and prostate-specific antigen. Specifically, blood levels of prostate-specific antigen (PSA), a protein that is used as a marker for the disease, decreased by 42 per cent after supplementation. Blood lycopene concentrations increased by 88 per cent. In the control group, PSA levels increased by 23 per cent, while serum lycopene levels decreased by 52 per cent. Being a vegetable carotenoid, lycopene is safe for longer-term uses without any adverse reaction.
Potential applications: Lycopene has an effective association with a reduced risk of prostate cancer.
+972 8 6296630
To submit newly published research on your company's ingredients, please email [email protected] for details.